Perfluorooctanoic acid affects mouse brain and liver tissue through oxidative stress

Burcu Ünlü Endirlik1,2, Ayşe Eken1, Hande Canpinar3, Figen Öztürk4, and Aylin Gürbay2

1 Erciyes University Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Kayseri, Turkey
2 Hacettepe University Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Turkey
3 Hacettepe University Cancer Institute, Department of Basic Oncology, Ankara, Turkey
4 Erciyes University Faculty of Medicine, Department of Pathology, Kayseri, Turkey

[Received in February 2022; Similarity Check in February 2022; Accepted in April 2022]

The aim of this study was to investigate oxidative stress induced by perfluorooctanoic acid (PFOA) in the brain and liver tissues of Balb/c mice as well as protective effects of taurine and coenzyme Q10 (CoQ10) in both organs. For this purpose, animals were treated with PFOA (15 and 30 mg/kg) orally and their lipid peroxidation, total glutathione levels (GSH), and antioxidant enzyme activities measured and both tissues analysed for histopathological changes. Our results showed a dose-dependent decrease in body weight and increase in relative brain and liver weights, PFOA-induced lipid peroxidation and reduced glutathione peroxidase (GPx) activity in the brain tissue, and changes in GSH levels, GPx, superoxide dismutase (Cu-Zn SOD), and catalase (CAT) activities in the liver tissue. Pre-treatment with taurine or CoQ10 provided protection against PFOA-induced Cu-Zn SOD reduction in the liver tissue. Our findings evidence the depleting effect of PFOA on antioxidative systems and confirm that PFOA exerts its (neuro)toxicity through oxidative stress, but further research is needed to identify the exact toxicity mechanisms, especially in the brain.

KEY WORDS: body weight; CAT; CoQ10; GPx; GSH; hepatotoxicity; in vivo; neurotoxicity; oxidative damage; PFOA; relative organ weight; SOD; taurine

Perfluorooctanoic acid (PFOA), a member of polyfluorinated compounds, is an environmentally persistent chemical with a wide range of industrial use due to its oil and water-repellent properties and heat and chemical reaction resistance. The major human exposure pathways include consumption of contaminated food and water as well as inhalation of dust. Daily PFOA exposure for general population is estimated to be 0.3–150 ng/kg (1–5). PFOA and related substances have been included in the list of restricted substances in Annex XVII to the EU Registration, Evaluation, Authorization and Restriction of Chemicals regulation (6). PFOA is also classified as possibly carcinogenic to humans (Group 2B) by the International Agency for Research on Cancer (IARC) (7).

Animal studies show that PFOA is primarily distributed in the liver and plasma, with lower concentrations reaching other organs, including the brain (8–10). In humans, it is found in serum, breast milk, liver, kidneys, lungs, seminal plasma, thyroid gland, bones, and brain (11–15), confirming its ability to cross the blood-brain barrier. In addition, considerable levels of PFOA have been reported globally in human serum. In the United States, mean serum level reported in the general population is 3.7 ng/mL (16) and as high as 428–12000 ng/mL in occupationally exposed workers (17). Its estimated half-life in retired fluorochemical production workers is 3.8 years (18).

Several epidemiological and animal studies have shown a relationship between exposure to PFOA and adverse health effects in many organs and systems (2, 3), liver in particular (19, 20). However, knowledge about the effects of PFOA in the brain tissue is relatively scarce, even though the nervous system seems to be one of the most sensitive targets for this compound (21). In addition, due to its long serum half-life and ability to cross the placenta, PFOA raises concern about normal brain development especially in foetuses and newborns (22, 23).

The underlying mechanism of adverse effects has not been entirely explained, but numerous in vivo (24, 25) and in vitro (26–28) studies point to oxidative stress. The aim of our study was to look further into oxidative stress induced by PFOA in mouse brain and liver tissue and to see whether known antioxidants, taurine and coenzyme Q10 (CoQ10) can provide any protection.

MATERIALS AND METHODS

Chemicals

PFOA (ammonium salt of perfluorooctanoic acid, 96%), taurine, and CoQ10 were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Haematoxylin and eosin yellowish were obtained from Merck.
LD 30 mg/kg bw) for 10 days. Both doses are much lower than oral oil) in the same volume and route for 10 days.

Control animals received the vehicle (distilled water or corn gavage in the volume of 10 mL/kg body weight (bw) at doses given below. Control animals received the vehicle (distilled water or corn oil) in the same volume and route for 10 days.

PFOA and taurine were dissolved in Milli-Q water and CoQ 10 in corn oil. All solutions were freshly prepared, protected from light, and administered to the animals by gavage in the volume of 10 mL/kg body weight (bw) at doses given below. Control animals received the vehicle (distilled water or corn oil) in the same volume and route for 10 days.

All animals were sacrificed by cervical dislocation under ketamine/ xylazine (90/10 mg/kg bw) anaesthesia 24 h after receiving the last treatment dose. Body weights were taken before sacrifice. Whole brain and liver were removed, washed with ice-cold 0.9 % NaCl, blotted, dried, and weighed. Small tissue sections were fixed in formalin for histopathological examination. The remaining parts of the tissues were stored at -80 °C until biochemical and flow cytometric analysis.

Fixed tissue samples with 10 % neutral formalin were dehydrated with gradient ethanol solution and embedded in paraffin. The samples were then sliced to 5-µm slices with an automatic microtome. After staining with haematoxylin and eosin, pathological changes were observed under a Nikon Optiphot 2 light microscope (200× magnification, Tokyo, Japan).

The tissues were homogenised in 1.15 % KCl using glass-glass Potter-Elvehjem-type homogeniser to obtain 10 % (w/v) whole homogenates. A part of a whole homogenate was used to determine malondialdehyde (MDA) level, and the rest was centrifuged at 1500 g and 4 °C for 10 min. Collected supernatant was used to measure total glutathione (GSH) and antioxidant enzyme activities. For total GSH analysis, a part of the obtained supernatant was diluted with metaphosphoric acid (6 %), re-centrifuged at 1500 g and 4 °C for 10 min for further use. The other part of the supernatant was re-centrifuged at 9500 g and 4 °C for 25 min for determination of enzyme activities.

Lipid peroxidation was determined spectrophotometrically as described by Okhawa et al. (38). The method measures the absorbance of thiobarbituric acid-reactive substances (TBARS) from the reaction of thiobarbituric acid (TBA) with MDA. TBARS levels are expressed in nanomoles of MDA per mg of protein.

Total tissue GSH concentration was measured using the method described by Akerboom and Sies (39). This method is based on continuous reduction of 5,5′-dithiobis(2-nitrobenzoic acid) to 5′-thionitrobenzoate by NADPH in a reaction catalysed by glutathione reductase in the presence of GSH. Total GSH was determined by spectrophotometric monitoring of reaction kinetics at 412 nm. Results are expressed as µmol/mg protein.

Brain and liver copper-zinc superoxide dismutase (Cu-Zn SOD) activities were determined using the method described by Arthur and Boyne (40) with slight modifications. Glutathione peroxidase (GPx) and catalase (CAT) activities were measured as described by Pleban et al. (41) and Aebi (42), respectively. All enzyme activities are expressed as units per mg protein (U/mg protein). Protein content in brain and liver homogenates and supernatants was determined as described by Lowry et al. (43). This method is based on measuring the absorbance of blue-coloured complex formed following the reaction of tyrosine and tryptophan residues with alkaline copper and Folin-Ciocalteu reagent at 540 nm.

Liver tissue samples were minced with a blade, suspended in phosphate buffer saline (PBS), filtered through a 37 µm pore nylon mesh, and centrifuged at 400 g. Liver cells isolated from all the experimental groups were fixed in 80% ethanol at 4 °C overnight and centrifuged, and washed with and resuspended in PBS. After adding RNase and propidium iodide, liver cells incubated at 37 °C for 1 h. Fluorescence was measured for 10,000 cells with flow cytometry (EPICS XL MCL, Beckman Coulter Inc., Brea, CA, USA), based on which we were able to determine DNA content histograms with MultiCycle software from Phoenix Flow Systems (San Diego, CA, USA) and calculate the percentage of cells in respective phases (G1, S, and G2/M) of the cell cycle.

All data are expressed as medians and interquartile ranges save for the results of cell-cycle analysis results, which were reported as...
medians. Kruskal-Wallis test was followed by the Mann-Whitney *U* test for analysing the statistical difference between control and treated groups using Statistical Package for the Social Sciences for Windows (SPSS, version 18.0; Chicago, IL, USA). A value of *p*<0.05 was considered statistically significant.

**RESULTS**

**Body and organ weights**

Body weights of mice treated with both doses of PFOA significantly decreased in a dose-dependent manner (Table 1) compared to control (12% and 21%, respectively, *p*<0.05). Relative brain weight significantly increased only in the 30 mg/kg PFOA group (21%, *p*<0.05), while relative liver weights were significantly higher in both PFOA groups (291% and 293%, respectively, *p*<0.01). Both antioxidants seemed ineffective against PFOA-induced weight changes.

**Histopathological changes**

Histology of brain sections appeared normal in all groups (Figure 1). No significant abnormalities were detected in the neuronal or glial cells of the brain tissue. Livers also had normal histological appearance in the control, taurine, corn oil, and CoQ<sub>10</sub>-treated groups (Figure 2, panels A, D, F, and G) with no significant changes in portal tracts and central veins. However, all PFOA-treated (Figure 2, panels B and C) and antioxidant+PFOA-treated groups (Figure 2, panels E and H) showed hepatocellular hypertrophy, necrosis, balloon degeneration, and eosinophilic cytoplasmic changes, whereas the 30 mg/kg PFOA group also showed more prominent necrosis (Figure 2, panel C).

**Table 1** Body weight and relative brain and liver weight changes in mice treated with oral PFOA, CoQ<sub>10</sub>, and taurine

| Groups             | Body weight change from baseline (%) | Relative brain weight (g/100 g) | Relative liver weight (g/100 g) |
|--------------------|--------------------------------------|---------------------------------|---------------------------------|
| Control (water)    | 3.03 (-6.43—8.14)                    | 1.25 (1.19—1.36)               | 5.39 (5.00—5.82)               |
| PFOA (15 mg/kg)    | -11.76* (-14.71—8.33)               | 1.50 (1.30—1.62)               | 15.71d (14.67—15.91)           |
| PFOA (30 mg/kg)    | -21.21* (-28.57—0)                  | 1.51* (1.27—1.65)              | 15.79* (15.00—17.44)           |
| Taurine            | -3.23 (-10.81—2.56)                 | 1.28 (1.18—1.45)               | 5.09 (5.03—5.59)               |
| Taurine + PFOA     | -13.33 (-16.67—3.23)                | 1.46 (1.32—1.54)               | 16.00* (15.71—16.40)           |
| Corn oil           | -4.37 (-12.42—2.03)                 | 1.33 (1.19—1.48)               | 5.47 (4.58—6.25)               |
| CoQ<sub>10</sub>   | -7.89 (-8.33—0)                     | 1.30 (1.24—1.36)               | 5.15 (5.15—5.37)               |
| CoQ<sub>10</sub> + PFOA | -17.65b (-22.86—9.38)           | 1.37 (1.36—1.56)               | 15.86f (13.09—17.04)           |

Data are expressed as medians and interquartile ranges (n=6 for water and corn oil groups; n=7 for treated groups). *p*<0.05 and *dp*<0.01 relative to control; *bp*<0.05 and *fp*<0.01 relative to control; *p*<0.05 and *dp*<0.01 relative to control; *p*<0.05 and *dp*<0.01 relative to control; *ep*<0.01 relative to taurine.

![Figure 1](image-url) **Figure 1** Histopathological changes in mouse brain tissue stained with hematoxylin and eosin (200× magnification). A – control; B – PFOA dose of 15 mg/kg bw; C – PFOA dose of 30 mg/kg bw; D – taurine dose of 100 mg/kg bw; E – taurine+PFOA dose of 30 mg/kg bw; F – corn oil; G – CoQ<sub>10</sub> dose of 50 mg/kg bw; H – CoQ<sub>10</sub>+PFOA dose of 30 mg/kg bw
Figure 2 Histopathological changes in mouse liver tissue stained with hematoxylin and eosin (200× magnification). A – control; B – PFOA dose of 15 mg/kg bw; C – PFOA dose of 30 mg/kg bw; D – taurine dose of 100 mg/kg bw; E – taurine+PFOA dose of 30 mg/kg bw; F – corn oil; G – CoQ10 dose of 50 mg/kg bw; H – CoQ10+PFOA dose of 30 mg/kg bw. Arrows: CV – central vein; H – hepatocellular hypertrophy; E – eosinophilic cytoplasm; B – balloon degeneration; FN – focal necrosis; N – necrosis; A – acidophilic cytoplasm

Figure 3 Total MDA and GSH levels in brain and liver tissues of mice treated with PFOA, taurine, and CoQ10 (data are expressed as medians and interquartile ranges, n=6 for water and corn oil groups; n=7 for treated groups). *p<0.05 and *p<0.01 relative to control; †p<0.01 and ‡p<0.05 relative to taurine; §p<0.01 relative to PFOA (30 mg/kg); ¶p<0.05 and ¶¶p<0.01 relative to corn oil; ‡‡p<0.05 and ‡‡‡p<0.01 relative to CoQ10
Lipid peroxidation and GSH levels

Significant changes were observed in brain MDA levels, which increased 1.22 times (p<0.01) in the 30 mg/kg PFOA group (Figure 3), and liver GSH, which increased 1.15 times in the 15 mg/kg PFOA group and 1.09 times in the 30 mg/kg PFOA group (Figure 3).

Neither antioxidant seemed to be effective against brain MDA or liver GSH increase. However, liver MDA levels decreased below control in animals pretreated with taurine or CoQ_{10} plus PFOA (Figure 3).

Antioxidant enzyme activities

Brain Cu-Zn SOD activities were not affected by PFOA treatment. However, both PFOA doses significantly decreased liver Cu-Zn SOD activities in a dose-dependent manner (Figure 4) relative to control (42 % with the lower and 53 % with the higher dose;
p<0.01). GPx activity in both tissues significantly dropped in both PFOA groups (18% with the lower and 17% with the higher dose in the brain and 67% with the lower and 75% with the higher dose in the liver; p<0.01 for all comparisons) (Figure 4). Lower and higher PFOA dose also significantly increased liver CAT activity (37% and 24%, respectively, p<0.01), whereas no significant change was observed in the brain tissue.

Taurine and CoQ10 were ineffective against PFOA-lowered GPx activity in the brain tissue, but significantly countered the effects of 30 mg/kg PFOA on SOD activity (p<0.01) in the liver. Furthermore, given alone, they significantly increased liver GPx activities relative to control (p<0.01). However, the two antioxidants differed in their effects against PFOA-induced CAT changes in the liver, as taurine pretreatment increased it significantly (p<0.01) and CoQ10 pretreatment lowered it significantly (p<0.01) relative to the 30 mg/kg PFOA group.

Liver cell cycle and apoptosis findings

Neither PFOA dose significantly affected liver cell cycle (Figure 5). With significantly more cells found in the G0/G1 phase than observed with the higher PFOA dose (p<0.05), taurine led to cell cycle arrest, whereas CoQ10 increased cell proportion in the G2/M phase.

DISCUSSION

Significant drops in body weight and increases in relative brain (with the higher PFOA dose) and liver weights (with both doses) in our study support earlier reports of PFOA effects (44–48). Unlike some reports (48, 49), however, we observed no significant histopathological changes in the brain at either PFOA dose, which may be owed to differences between animal species or in PFOA doses and treatment duration. On the other hand, in addition to hepatomegaly, we observed histopathological changes in the liver, including eosinophilic cytoplasm, ballooning degeneration, and necrosis, which is in line with earlier reports (20, 31, 46). Cui et al. (49) suggested that hepatomegaly might be attributed to the proliferation of peroxisome, smooth endoplasmic reticulum, and mitochondria. As a peroxisome proliferator, PFOA increases β-oxidation of peroxisomal fatty acids as well as the number and size of peroxisomes, which in turn leads to a series of morphological and biochemical changes, including hepatocellular hypertrophy (19).

As regards oxidative stress, our findings of significantly increased MDA levels in the brain tissue at the higher PFOA dose and lower GPx activity at both doses seem to corroborate earlier reports of its involvement in neurotoxic action of PFOA, including adverse developmental and behavioural effects in children (23, 27, 50–56).

As for the liver tissue, some studies suggest that PFOA induces lipid peroxidation (20, 24, 57), while others do not (32, 45, 51), and our findings are in line with the latter group. However, other oxidative stress parameters in the liver seem to have been affected by PFOA treatment, such as GSH as initial cell defence mechanism against oxidative stress or CAT, which increased significantly as reported elsewhere (32, 58–60) or Cu-Zn SOD and GPx activities, which dropped due to depletion or deactivation (24, 61–63). Increases in CAT activity, which is present in peroxisomes and

![Figure 5](image-url) Distribution of liver cells by cycle in mice treated with PFOA, taurine, and CoQ10 (data are expressed as medians, n=3). *p<0.05 relative to the PFOA (30 mg/kg) group.
responsible for the reduction of $\text{H}_2\text{O}_2$ may be owed to reaction to higher prooxidant activity (58, 62), but when this prooxidant activity overcomes the protective capacity of CAT, its activity drops (64). The decline in SOD and GPx activities under PFOA exposure suggests that the effect of oxidative stress exceeds the antioxidant capacity of these enzymes, while increasing CAT levels might demonstrate counteraction of cells against oxidative damage.

Speaking of antioxidative action, both antioxidants in our study seem to be ineffective against PFOA-induced lipid peroxidation and GPx reduction in the brain. Other animal studies also reported inconsistent protective effects of taurine and CoQ$_{10}$ against oxidative stress induced by a variety of agents (35, 65–67). Differences between our and other studies that found stronger antioxidant effects of taurine and CoQ$_{10}$ may be owed to differences in protocol, as they used coin treatment instead of pretreatment. Nonetheless, our results confirm some antioxidative potential of taurine and CoQ$_{10}$ against PFOA-induced oxidative stress in the liver, as both substances significantly increased SOD activity and lowered MDA levels in pretreatment with the lower PFOA dose, while maintaining GSH at control levels. However, only CoQ$_{10}$ restored CAT activity to near control values.

As regards liver cell cycle distribution, we have shown that PFOA slightly increases the number of cells in the G0/G1 phase, which is in agreement with Shabalina et al. (68), and slightly decreases the number of cells in the G2/M phase. These results suggest that PFOA is capable of arresting cells in the G1 phase and of causing apoptosis and necrosis, probably by a pathway mediated by ROS and mitochondria reported elsewhere (45). Our study, however, has not detected apoptotic liver cells despite evidenced oxidative stress. This suggests that it takes higher PFOA doses or longer exposure for apoptosis to take place as reported in various studies mentioned above.

**CONCLUSION**

Our findings are important inasmuch as they evidence a depleting effect of PFOA on antioxidant systems, which corroborates earlier reports that PFOA induces oxidative stress and generates free radicals. They also show higher susceptibility of the brain tissue to PFOA because of its lower antioxidative capacity than liver. This points to a higher risk of neurodegenerative diseases and cancer and calls for more detailed investigation to understand the underlying oxidative stress mechanisms in different model systems.

**Acknowledgments**

This research was financially supported by the Hacettepe University Research Foundation (grant No. 013 D05 301 001).

**Conflict of interests**

None to declare.

**REFERENCES**

1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Perfluoroalkyls, 2021 [displayed 24 April 2022]. Available at https://www.atsdr.cdc.gov/ToxProfiles/pf20.pdf
2. Lau C, Aitkole K, Hodes C, Lai D, Pfahle-Hutcheson A, Seed J. Perfluorooalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007;99:366–94. doi: 10.1093/toxsci/kfm128
3. Lindstrom AB, Strynar MJ, Libelo EL. Polylfluorinated compounds: past, present, and future. Environ Sci Technol 2011;45:7954–61. doi: 10.1021/es2011622
4. Post GB, Cohn PD, Cooper KR. Perfluoroalkanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. Environ Sci Technol 2012;16:93–117. doi: 10.1016/j. envres.2012.03.007
5. Ünlü-Endirlik B, Bakır E, Bögelmey Zı, Eken A, Narin İ, Gürbey A. Assessment of perfluoroalkyl substances levels in tap and bottled water samples from Turkey. Chemosphere 2019;235:1162–71. doi: 10.1016/j.chemosphere.2019.06.228
6. European Union (EU) Commission regulation 2017/1000 of 13 June 2017 amending Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards perfluorooctanoic acid (PFOA), its salts and PFOA-related substances [displayed 03 February 2022]. Available at https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R1000&from=EN
7. International Agency for Research on Cancer (IARC). Some Chemicals Used as Solvents and in Polymer Manufacture IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 110 [displayed 03 February 2022]. Available at https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Chemicals-Used-As-Solvents-And-In-Polymer-Manufacture-2016
8. Ahrens I, Siebert U, Ebinghaus R. Total body burden and tissue distribution of polylfluorinated compounds in harbor seals (Phoca vitulina) from the German Bight. Mar Pollut Bull 2009;58:520–5. doi: 10.1016/j.marpolbul.2008.11.030
9. Hundle S, Sarif A, Kennedy Jr G. Absorption, distribution, and excretion of ammonium perfluorooctanoate (APFO) after oral administration to various species. Drug Chem Toxicol 2006;29:137–45. doi: 10.1080/01480406085161361
10. Kudo N, Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci 2003;28:49–57. doi: 10.2131/jts.28.49
11. Maestri L, Negri S, Ferrari M, Ghittori S, Fabris F, Danesino P, Imbriani M. Determination of perfluorooctanoic acid and perfluorooctanesulfonate in human tissues by liquid chromatography/single quadrupole mass spectrometry: Rapid Commun Mass Spectrom 2006;20:2728–34. doi: 10.1002/rcm.2661
12. Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 2003;45:260–70. doi: 10.1097/01. jom.0000052958.59271.10
15. Pérez F, Nadal M, Navarro-Ortega A, Fábrega F, Domingo JL, Barceló D, Farré M. Accumulation of perfluoroalkyl substances in human tissues. Environ Int 2013;59:354–62. doi: 10.1016/j.envint.2013.06.004

14. Pirilä B, Negri S, Chytris E, Perissi A, Villani L, La Manna L, Cottica D, Ferrari M, Imbriani M, Rotondi M, Chiavoto L. Perfluorooctane sulfonate and perfluorooctanoic acid in surgical thyroid specimens of patients with thyroid disease. Thyroid 2009;19:1407–12. doi: 10.1089/thy.2009.0174

15. Tao L, Mi J, Kunische T, Läbel EL, Tanabe S, Kannan K. Perfluorinated compounds in human breast milk from several Asian countries, and in infant formula and dairy milk from the United States. Environ Sci Technol 2008;42:8597–602. doi: 10.1021/es801875v

16. Calafat AM, Kuklenyik Z, Reidy JA, Caudill, SP, Tully JS, Needham LL. Serum concentrations of 11 perfluoroalkyl compounds in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ Sci Technol 2007;41:2237–42. doi: 10.1021/es0628680

17. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 2010;118:1100–8. doi: 10.1289/ehp.0901827

18. Olsen GW, Burris JM, Ehresman DJ, Froelich JW, Seah AM, Butenhoff JL, Zobel LR. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007;115:1298–305. doi: 10.1289/ehp.10009

19. Son H-Y, Kim S-H, Shin H-I, Bae H, Yang J-H. Perfluorooctanoic acid-induced hepatic toxicity following 21-day oral exposure in mice. Arch Toxicol 2008;82:239–46. doi: 10.1007/s00204-007-0246-x

20. Zou W, Liu W, Yang B, Luo L, Xu R, Xie L, Zhang L. Quercetin protects against perfluorooctanoic acid-induced liver injury by attenuating oxidative stress and inflammatory response in mice. Int Immunopharmacol 2015;28:129–35. doi: 10.1016/j.intimp.2015.05.043

21. Mariussen E. Neurotoxic effects of perfluorooctylated compounds: mechanisms of action and environmental relevance. Arch Toxicol 2012;86:1349–67. doi: 10.1007/s00204-012-0822-6

22. Hoyer BB, Ramlau-Hansen CH, Obel C, Pedersen HS, Hernik A, Ogniev V, Jönsson BA, Lindh CH, Rylander L, Rignell-Hydbom A, Butenhoff JL, Zobel LR. Half-life of serum elimination of PFOS and PFOA in retired fluorochemical production workers. Environ Health Perspect 2008;116:1308–11. doi: 10.1289/ehp.0701442

23. Song HS, Kim HR, Park TW, Cho BJ, Choi MY, Kim CJ, Sohn UD. Cadmium-induced neurological disorders: Possible role of microglia inhibition. Pharmacol Rep 2010;62:178–82. doi: 10.1016/j.pr.2009.11.007

24. Sinha M, Pannu P, Sil PC. Cadmium-induced neurological disorders: prophylactic role of coenzyme Q10 on diabetic neuropathic pain in a mouse model of type 1 diabetes. Anesthesiology 2013;118:945–54. doi: 10.1097/ALN.0b013e3182829b7b

25. Ohkawa H, Oishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8. doi: 10.1016/0003-2697(79)90738-3

26. Axelrod BL, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 1981;77:373–82. doi: 10.1016/0076-6879(81)77050-2

27. Arthur J, Boyne R. Superoxide dismutase and glutathione peroxidase activities in neutrophils from selenium deficient and copper deficient cattle. Life Sci 1985;36:1659–75. doi: 10.1016/0024-3205(85)90381-9

28. Pleban PA, Munyani A, Beachum J. Determination of selenium concentration and glutathione peroxidase activity in plasma and erythrocytes. Clin Chem 1982;28:311–6. doi: 10.1093/clinchem/28.2.311

29. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121–6. doi: 10.1016/0070-6379(84)50163-3
42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75. PMID: 14907713

43. Butenhoff JL, Kennedy GL Jr., Chang SC, Olsen GW. Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology 2012;298:1–13. doi: 10.1016/j.tox.2012.04.001

44. Crebelli R, Ciola S, Conti I, Cordelli E, De Luca G, Dellettre E, Eleuteri P, Iacovella N, Leopardi P, Marcon F, Sanchez M, Sestili P, Siniscalchi E, Villani P. Can sustained exposure to PFAS trigger a genotoxic response? A comprehensive genotoxicity assessment in mice after subacute oral administration of PFOA and PFBA. Regul Toxicol Pharmacol 2019;106:169–77. doi: 10.1016/j.yrtph.2019.05.005

45. Li D, Zhang L, Zhang Y, Guan S, Gong X, Wang X. Maternal exposure to perfluorooctanoic acid (PFOA) causes liver toxicity through PPAR-α pathway and lowered histone acetylation in female offspring mice. Environ Sci Pollut Res Int 2019;26:18866–75. doi: 10.1007/s11356-019-05258-z

46. Asakawa A, Toyoshima M, Fujimiyama M, Harada K, Ataka K, Inoue K, Koizumi A. Perfluorooctane sulfonate influences feeding behavior and gut motility via the hypothalamus. Int J Mol Med 2007;19:733–7. PMID: 17390077

47. Shi L, Zheng J, Yan S, Li Y, Wang Y, Liu X, Xiao C. Exposure to perfluorooctanoic acid induces cognitive deficits via altering gut microbiota composition, impairing intestinal barrier integrity, and causing inflammation in gut and brain. J Agric Food Chem 2020;68:13916–28. doi: 10.1021/acs.jafc.0c05834

48. Cui L, Zhou QF, Liao CY, Fu JJ, Jiang GB. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch Environ Contam Toxicol 2009;56:338–49. doi: 10.1007/s00244-008-9194-6

49. Salimi A, Nikooiasr Jahromi M, Pourahmad J. Maternal exposure causes mitochondrial dysfunction in brain, liver, and heart of mouse fetus: an explanation for perfluorooctanoic acid induced abortion and developmental toxicity. Environmen Toxicol 2019;34:878–85. doi: 10.1002/tox.22760

50. Mashayekhi V, Taheri KH, Hashemzaei M, Tabrizian K, Shahraki J, Kheirandish MN, Hossini MH, Hosseini MJ. Mechanistic approach for the toxic effects of perfluorooctanoic acid on isolated rat liver and brain mitochondria. Hum Exp Toxicol 2015;34:985–96. doi: 10.1177/0960327114565492

51. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2002;1:1038–49. doi: 10.1038/nrd1330

52. Kneecik M, da Costa MC, de Oliveira Ribeiro CA, Ortolani-Machado CF. Morphological evidence of neurotoxic effects in chicken embryos after exposure to perfluorooctanoic acid (PFOA) and inorganic cadmium. Toxicology 2019;427:152286. doi: 10.1016/j.tox.2019.152286

53. Oh J, Bennett DH, Calafat AM, Tancredi D, Roa DL, Schmidt RJ, Hertz-Picciotto I, Shin HM. Prenatal exposure to per- and polyfluoroalkyl substances in association with autism spectrum disorder in the MARBLES study. Environ Int 2021;147:106328. doi: 10.1016/j.envint.2020.106328

54. Ghassabian A, Bell EM, Ma WL, Sundaram R, Kannan K, Louis GM, Yeung E. Concentrations of perfluoralkyl substances and bisphenol A in newborn dried blood spots and the association with child behavior. Environ Pollut 2018;243:1629–36. doi: 10.1016/j.envpol.2018.09.077

55. Lenters V, Issart N, Forns J, Cechová E, Kočan A, Legler J, Leonards P, Stigum H, Egggesbo M. Early-life exposure to persistent organic pollutants (OCPs, PBDEs, PCBs, PFASs) and attention-deficit/hyperactivity disorder: A multi-pollutant analysis of a Norwegian birth cohort. Environ Int 2019;125:33–42. doi: 10.1016/j.envint.2019.01.020

56. Kamendulis LM, Wu Q, Sandusky GE, Hocevar BA. Perfluorooctanoic acid exposure triggers oxidative stress in the mouse pancreas. Toxicol Rep 2014;1:153–21. doi: 10.1016/j.toxrep.2014.07.015

57. Ahmed DY, El-Haj RA. Effect of exposure to perfluorooctanoic acid on hepatic antioxidants in mice. Comp Clin Pathol 2012;21:1643–5. doi: 10.1007/s00580-011-1341-1

58. Chen LC, Tatum V, Glauert HP, Chow CK. Peroxisome proliferator perfluorooctanoic acid alters glutathione and related enzymes. J Biochem Mol Toxicol 2001;15:107–13. doi: 10.1002/jbt.6

59. Xu M, Wang J, Niu Q, Liu R. PFOA and PFOS interact with superoxide dismutase and induce cytotoxicity in mouse primary hepatocytes: A combined cellular and molecular methods. Environ Res 2019;175:63–70. doi: 10.1016/j.envres.2019.05.008

60. Tang J, Jia X, Gao N, Wu Y, Liu Z, Lu X, Du Q, He J, Li N, Chen B, Jiang J. Role of the Nrf2-ARE pathway in perfluorooctanoic acid (PFOA)-induced hepatotoxicity in Rana nigromaculata. Environ Pollut 2018;238:1033–43. doi: 10.1016/j.envpol.2018.02.037

61. Liu C, Yu K, Shi X, Wang J, Lams PK, Wu RS, Zhou B. Induction of oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of Oryzias latipes. Aquat Toxicol 2007;82:135–43. doi: 10.1016/j.aquatox.2007.02.006

62. Yang S, Liu S, Ren Z, Jiao X, Qin S. Induction of oxidative stress and related transcriptional effects of perfluorooctanoic acid using an in vivo assessment. Comp Biochem Physiol C Toxicol Pharmacol 2014;160:60–5. doi: 10.1016/j.cbpc.2013.11.007

63. Xu D, Li C, Chen H, Shao B. Cellular response of freshwater green algae to perfluorooctanoic acid toxicity. Ecotoxicol Environ Saf 2013;88:103–7. doi: 10.1016/j.ecoenv.2012.10.027

64. Akande M, Aliu Y, Ambali S, Ayo J. Taurine mitigates cognitive impairment induced by chronic co-exposure of male Wistar rats to chlorpyrifos and lead acetate. Environ Toxicol Pharmacol 2014;37:25–35. doi: 10.1016/j.etap.2013.11.023

65. Majumdar AS, Nirwane A, Kamble R, Coenzyme q10 abrogated the 28 days aluminium chloride induced oxidative changes in rat cerebral cortex. Toxicol Int 2014;21:214–21. doi: 10.4103/0971-6580.139814

66. Nassoohi S, Simani L, Khodagholi F, Niskeresh S, Faizi M, Naderi N. Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutr Neurosci 2019;22:264–72. doi: 10.1080/1028415X.2017.1376928

67. Shabalina IG, Panaretakis T, Bergstrand A, DePierre JW Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells. Carcinogenesis 1999;20:2237–46. doi: 10.1093/carcin/20.12.2237
Perfluorooktanoična kiselina oštećuje moždano i jetreno tkivo putem oksidacijskoga stresa

Cilj je ovog istraživanja bio utvrditi oksidacijski stres prouzročen perfluorooktanoičnom kiselinom (PFOA) u moždanom i jetrenom tkivu Balb/c miševa te zaštitno djelovanje taurina i koenzima Q₁₀ (CoQ₁₀) u oba organa. U tu su svrhu životinje izložene PFOA-i u oralnoj dozi od 15 ili 30 mg/kg tjelesne težine te su u oba tkiva analizirane histopatološke promjene i izmjerenje lipidna peroksidacija, ukupne razine glutationa (GSH) i aktivnosti antioksidacijskih enzima. Naši rezultati pokazuju smanjenje ukupne tjelesne težine i povećanje relativne težine organa ovisne o dozi, lipidnu peroksidaciju i smanjenu aktivnost glutation peroksidaze (GPx) u moždanom tkivu te promjene razina GSH i aktivnosti GPx, superoksid dismutaze (Cu-Zn SOD) i katalaze (CAT) u jetrenom tkivu. Prethodna primjena taurina ili CoQ₁₀ zaštitila je životinje izložene PFOA-i od pada razina Cu-Zn SOD u jetrenom tkivu. Naši rezultati potvrđuju da PFOA iscrpljuje antioksidacijske sustave i djeluje (neuro)toksično putem oksidacijskoga stresa, no potrebna su daljnja istraživanja kako bi se precizno utvrdili njegovi mehanizmi toksičnosti, napose u mozgu.

KLJUČNE RIJEČI: CAT; CoQ₁₀; GPx; GSH; hepatotoksičnost; in vivo; neurotoksičnost; oksidacijsko oštećenje; PFOA; relativna masa organa; SOD; taurin; tjelesna masa